Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Platelet-pheresis Clear all
Terminated Phase 3 Interventional Results available

Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)

NCT00799773
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
Rituximab, Plasma exchange, Corticosteroids
Drug · Procedure
Lead sponsor
Carelon Research
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2013 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional

rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

NCT00038012
View directory record Official record
Conditions
Neoplasms, Gynecologic
Interventions
Thrombopoietin, Platelet-pheresis, Carboplatin
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Differing Platelet Transfusion Times in Neonates

NCT00948792
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Short platelet transfusion, Long platelet transfusion
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

NCT06414889
View directory record Official record
Conditions
RUNX1 Familial Platelet Disorder
Interventions
G-CSF (filgrastim or biosimilar), Apheresis, Plerixafor
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of the CM-1500 During Apheresis Blood Donation

NCT05012462
View directory record Official record
Conditions
Fluid Loss
Interventions
CM-1500, CM-1600
Device
Lead sponsor
Zynex Monitoring Solutions
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Ex Vivo Expansion (ACT-X)

NCT07137312
View directory record Official record
Conditions
Solid Tumor, Healthy, Malignant Solid Neoplasm
Interventions
Blood Draw, Apheresis
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

NCT04631211
View directory record Official record
Conditions
Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders, Myelodysplastic Syndromes, Platelet Refractoriness
Interventions
Thrombosomes, Liquid Stored Platelets (LSP)
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Duarte, California • Washington D.C., District of Columbia • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT02098109
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions
XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

NCT06158828
View directory record Official record
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Cold Apheresis Platelets in PAS

NCT02754414
View directory record Official record
Conditions
Platelet Transfusion
Interventions
Apheresis platelet collection, Refrigerated storage of apheresis platelets in PAS/plasma, Infusion of aliquot of autologous radiolabeled platelets, In vitro tests
Procedure · Other · Radiation
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Not applicable Interventional

Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

NCT01810276
View directory record Official record
Conditions
Traumatic Head Injury, Intracranial Hemmorhage, Anti-platelet Therapy
Interventions
Saline, Platelets
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Withdrawn Phase 2 Interventional

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

NCT00723658
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Cold Stored Platelet in Hemorrhagic Shock

NCT04667468
View directory record Official record
Conditions
Trauma, Hemorrhage
Interventions
Cold Stored Platelets (CSP), Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
15 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.

NCT06697223
View directory record Official record
Conditions
Healthy Subjects
Interventions
INTERCEPT Blood System for Platelets with LED Illuminator
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Norfolk, Virginia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Trima Version 7.0 Platelets in 100% Plasma

NCT02754492
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Trima Accel System with Version 7.0 Software
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

NCT02653443
View directory record Official record
Conditions
Healthy
Interventions
Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets., Autologous apheresis Conventional untreated Platelet Components
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Lebanon, New Hampshire • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

NCT05011422
View directory record Official record
Conditions
Pediatric Hematologic Malignancies
Interventions
Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting Phase 1 Interventional

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

NCT06186401
View directory record Official record
Conditions
EGFR Gene Mutation, Glioblastoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
Interventions
E-SYNC T Cells, Cyclophosphamide (non-investigational), Fludarabine (non-investigational), Leukapheresis, Surgical resection
Biological · Drug · Procedure
Lead sponsor
Hideho Okada, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Trima Version 7.0 Platelets in PAS

NCT02754440
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Trima Accel System with Version 7.0 Software
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
San Diego, California • Denver, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Not applicable Interventional Results available

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

NCT02964325
View directory record Official record
Conditions
Hematologic Malignancies, Hypoproliferative Thrombocytopenia
Interventions
Mirasol platelets (MIR PLTs), Reference platelets (REF PLTs)
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
Not listed
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

NCT03097289
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Trima Accel system
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Active, not recruiting Phase 2 Interventional

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 7, 2026, 11:10 PM EDT